Finance

Lists
Why is PRQR down 2.76%?
Dive Deeper
PRQR:NASDAQ
ProQR Therapeutics NV
$1.58
-2.76%
(-0.045) 1D
Oct 12, 10:18:03 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRQR...
Open
$1.62
High
$1.62
Low
$1.57
Mkt. cap
223.68M
Avg. vol.
658.55K
Volume
113.35K
52-wk high
$3.10
52-wk low
$1.33
EPS
-$0.44
Beta
0.20
Shares outstanding
138.09M
No. of employees
187
Open
$1.62
High
$1.62
Low
$1.57
Mkt. cap
223.68M
Avg. vol.
658.55K
Volume
113.35K
52-wk high
$3.10
52-wk low
$1.33
EPS
-$0.44
Beta
0.20
Shares outstanding
138.09M
No. of employees
187
News stories
From web sources and news partners
Profile
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
About ProQR Therapeutics NV
CEODaniel A. de Boer
Employees187
Founded2012
Headquarters-
SectorBiotechnology
Websiteproqr.com
Analyst ratings
Based on 4 analysts giving stock ratings to PRQR in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for PRQR in the last 3 months.
Highest
Current $1.58
$9.00 (+467.82%)
Average
$8.25 (+420.50%)
Lowest
$8.00 (+404.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$8.00
+404.7%
10/01/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$8.00
+404.7%
09/30/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$8.00
+404.7%
08/14/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$9.00
+467.8%
08/14/2026
Ryan Deschner
Raymond James
Buy
Maintained
$10.00
+530.9%
06/26/2026
Catherine Novack
JonesTrading
Buy
Maintained
$10.00
+530.9%
06/26/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$3.00
+89.3%
06/25/2026
Jonathan Wolleben
Citizens JMP
Buy
Reiterated
$8.00
+404.7%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.92M
4.72M
2.03M
8.76M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11.08M
9.92M
11.83M
12.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.12M
3.89M
3.85M
4.91M
Operating expense
14.20M
13.81M
15.68M
17.58M
Total operating expenses
14.20M
13.81M
15.68M
17.58M
Operating income
-11.28M
-9.10M
-13.65M
-8.82M
Other non operating income
-2.00K
59.00K
54.00K
-33.00K
EBT including unusual items
-11.01M
-8.92M
-13.38M
-8.70M
EBT excluding unusual items
-11.01M
-8.92M
-13.38M
-8.70M
Income tax expense
-
1.00K
-
25.00K
Effective tax rate
-
-0.01%
-
-0.29%
Other operating expenses
-
-
-
-
Net income
-11.01M
-8.92M
-13.38M
-8.73M
Net profit margin
-377.56%
-189.14%
-658.29%
-99.65%
Earnings per share
-
-
-
-
Interest and investment income
280.00K
1.41M
212.00K
152.00K
Interest expense
-
-929.00K
-
-
Net interest expenses
280.00K
477.00K
212.00K
152.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.61M
-8.87M
-12.96M
-8.12M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps